A new article has been published in the August/September 2011 issue of the U.S. magazine Pharmaceutical Formulation & Quality, entitled "Cyclosporine - TBI's Miracle Drug". The article explains cyclosporine and the discovery of its potential as a new treatment for traumatic brain injury (TBI) indicating NeuroVive as the world leading pharmaceutical company developing these new drugs.
View article in PDF
Pharmaceutical Formulation & Quality
Responsible editor Eleonor Åsander Frostner eleonor.asander@neurovive.com Last updated: 2011-10-24
NeuroVive Pharmaceutical AB (publ), Biomedical Center, BMC D10, SE-221 84 Lund, Sweden
Tel: +46 (0)46 288 01 10 | Fax: +46 (0)46 888 83 48 | info@neurovive.com | Legal & Privacy